<prompt> Fingqa isihloko: Ukukhathazeka: Kunobufakazi obandayo bokuthi i - rosuvastatin ayisizi kangako kodwa inezinkinga ezingathi sína nakuba iyi - statin engcono kakhulu ekwehliseni i - cholesterol, kusho uDkt. Sidney Wolfe. I-statin enamandla inezinga eliphakeme lemiphumela emibi ehlanganisa ingozi eyengeziwe yesifo sikashukela, kuxwayisa umkhankaso oholayo namuhla. UDkt. Sidney Wolfe uthi kunobufakazi obandayo bokuthi i - rosuvastatin ayisizi kangako kodwa inezinkinga ezingathi sína nakuba iyi - statin engcono kakhulu ekwehliseni i - cholesterol. Ungumsunguli nomeluleki ophakeme we-Public Citizens Health Research Group, inhlangano yase-US elwela amalungelo abantu, eyazama ukuvimbela lo muthi eminyakeni eyishumi edlule ngenxa yezinkinga zemisipha nezinso. Uthi kusukela ngaleso sikhathi, ubufakazi babulokhu bukhula mayelana nezinzuzo ezingezinhle zalesi sidakamizwa. Ochwepheshe baseBrithani baye bathi ama-statin aphephile futhi ayasebenza, kanti ukuwavikela ekuhlaselweni yisifo senhliziyo kunamandla kunemiphumela engemihle. Omunye uye waqinisekisa iziguli ezithatha i - rosuvastatin, ethi kufanele ziqhubeke ziyithatha. Ama-statin yiwo ajwayele ukunqunywa kakhulu e-NHS futhi anikezwa abantu abadala abayizigidi ezingu-8 kuya kwezingu-10. Lokhu kuhlanganisa nalabo abanesifo senhliziyo noma abasengozini yokuhlaselwa yisifo senhliziyo noma unhlangothi. UDkt. Wolfe uthi ukuvunyelwa kokuqala kwe-rosuvastatin ukuze kuvinjelwe ukuhlaselwa yisifo senhliziyo eqenjini labantu abakhethiwe kakhulu kwakusekelwe ocwaningweni olwamiswa ngaphambi kwesikhathi. Lokhu kwaholela ekukhathazekeni ngokuthi imiphumela kungenzeka yayibekwe ngokweqile, uyanezela embhalweni wesihloko ephephabhukwini lezokwelapha i - BMJ. Ukubuyekezwa kwezivivinyo kwabonisa ukuthi lesi sidakamizwa, esaziwa nangokuthi iCrestor, sasihlotshaniswa nengozi eyengeziwe engamaphesenti angu-25 yesifo sikashukela uma siqhathaniswa ne-placebo, kusho yena. I-Crestor kwakuwumuthi womkhiqizo owawunikezwa kakhulu e-US ngonyaka odlule futhi wenza cishe amaphesenti amane emiyalelo ye-NHS yama-statin. UProfesa Peter Weissberg, umqondisi wezokwelapha eBritish Heart Foundation, wathi: Iziguli ezithatha i - rosuvastatin akufanele ziyeke ukuyithatha. Banaso isizathu esihle kakhulu sokwenza kanjalo. Ama-statin yiwo ajwayele ukunqunywa kakhulu eqenjini lemithi ku-NHS futhi anikezwa abantu abadala abaphakathi kwezigidi eziyisishiyagalombili kuya kweziyishumi. Lokhu...  <response>: Umkhankaso uthi i-rosuvastatin inezinga eliphezulu lemiphumela emibi. UDkt. Sidney Wolfe uthi kunobufakazi bokuthi kunezinzuzo ezincane nezinkinga. Ama-statin yiwo ajwayele ukunikezwa kakhulu e-NHS. Ochwepheshe bathi ukuvikeleka ekuhlaselweni yisifo senhliziyo kunemiphumela emibi. 